Lipopolysaccharide contamination in intradermal DNA vaccination : toxic impurity or adjuvant?
Publication date
2010-05
Authors
Berg, J.H. van den
Quaak, S.G.L.
Beijnen, J.H.
Hennink, W.E.
Storm, G.
Schumacher, T.N.
Haanen, J.B.A.G.
Nuijen, B.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Purpose: Lipopolysaccharides (LPS) are known both as potential adjuvants for vaccines and as toxic impurity in pharmaceutical preparations. The aim of this study was to assess the role of LPS in intradermal
DNA vaccination administered by DNA tattooing.
Method: Micewere vaccinated with a model DNA vaccine (Luc-NP) with an increasing content of residual
LPS. The effect of LPS on systemic toxicity, antigen expression and cellular immunity was studied.
Results: The presence of LPS in the DNA vaccine neither induced systemic toxicity (as reflected by IL-6
concentration in serum), nor influenced antigen expression (measured by intravital imaging). Higher LPS
contents however, appeared to be associated with an elevated cytotoxic T-lymphocyte (CTL) response but
without reaching statistical significance. Interestingly, the DNA tattoo procedure by itself was shown
to induce a serum cytokine response that was at least as potent as that induced by parenteral LPS
administration.
Conclusion: LPS does not show toxicity in mice vaccinated by DNA tattooing at dose levels well above
those encountered in GMP-grade DNA preparations. Thus, residual LPS levels in the pharmaceutical range
are not expected to adversely affect clinical outcome of vaccination trials and may in fact have some
beneficial adjuvant effect. The observed pro-inflammatory effects of DNA tattoo may help explain the
high immunogenicity of this procedure.
Keywords
DNA tattooing, DNA vaccination, LPS, Dermal delivery, Toxicology